Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Courage Under Fire
- Gleevec's discovery, development, and launch was a momentous experience that broke records at every stage: scientists delivering dramatic product efficacy never seen before in the history of cancer treatment; Novartis teams pulling together to greatly accelerate clinical trials, and rapid regulatory approvals. It seemed a perfect story. Indeed, to an...
- White papers 2003-04-01
Additional Resources
- Gleevec approved for first-line CML treatment
- The Food and Drug Administration FDA announced in late December the approval of Gleevec (imatinib mesylate; Novartis Pharmaceuticals Corporation) for the first-line treatment of patients with chronic myeloid leukemia CML. Gleevec was first approved inThe Food and Drug Administration FDA announced in late December the approval of Gleevec (imatinib mesylate;...
- Research articles 2003-03-01
- FDA approves Novartis' Gleevec for first line treatment of chronic myeloid leukemia
- Novartis Pharmaceuticals, East Hanover, NJ, received approval from the FDA for the use of Gleevec for first-line treatment of patients with chronic myeloid leukemia CML. Gleevec was first approved in May 2001 for the advanced stages of CML, under FDA's accelerated approval regulations. The drug was also indicated...
- Research articles 2002-12-27
- A short course of neoadjuvant Gleevec in dermatofibrosarcoma protuberans
- This study is currently recruiting patients. Verified and sponsored by University of Michigan Cancer Center. The goal of this research study is to see if Gleevec can be used to treat a rare type of tissue tumor, dermatofibrosarcoma protuberans DFSP. We would like to study the effects of the Gleevec...
- Research articles 2006-05-01
- NOVARTIS.(receives approval from Food and Drug Administration for Gleevec drug)(Brief Article)
- NOVARTIS has received FDA approval for its drug Gleevec (imatinib mesylate as an oral therapy for the treatment of patients ... NOVARTIS has received FDA approval for its drug Gleevec (imatinib mesylate as an oral therapy for the treatment of patients with chronic myeloid...
- Research articles 2001-05-14
- Novartis Completes Submissions in US and Europe for Gleevec(R) and GlaxoSmithKline Starting Study.
- M2 PRESSWIRE-11 April 2006-US Financial Network: Novartis Completes Submissions in US and Europe for GleevecR and GlaxoSmithKline Starting StudyC1994-2006 M2 COMMUNICATIONS LTD RDATE:11042006 City of Industry, CA - Pharmaceuticals industry news provided by Financial News USA (OTC: FNWU) Novartis (NYSE:NVS) announced...
- Research articles 2006-04-11
- Pricing of Novartis' Gleevec in Various Countries.
- M2 PRESSWIRE-14 January 2003-Research and Markets: Pricing of Novartis' Gleevec in Various CountriesC1994-2003 M2 COMMUNICATIONS LTD RDATE:01132003 Database Table: Pricing of Novartis' Gleevec in Various Countries Database Tables are proprietary data sources covering specific information for the...
- Research articles 2003-01-14
- Gleevec shown less effective in late-stage chronic myeloid leukemia
- Novartis confirmed published reports indicating the drug Gleevec (matinib mesylate, also known as STI+571) may be less effective in patients with advanced chronic myeloid leukemia. "Since the first clinical studies with Gleevec, research has shown that some patients at advanced stages respond to the drug initially, only to experience a...
- Research articles 2001-08-06
- Ambit Biosciences Publishes Data Identifying Drug Candidates That Counter Resistance to Gleevec, IRESSA and TARCEVA; Kinase Profiling Data Published in the Proceedings of the National Academy of Sciences
- SAN DIEGO -- Ambit Biosciences today announced that a study utilizing its novel kinase profiling technology revealed several existing clinical drug candidates that bind to and inhibit various mutations responsible for the development of resistance to the leading targeted cancer drugs GleevecR, IRESSAR and TARCEVATM. The study was published in...
- Research articles 2005-07-26
- Novartis' Gleevec goes to DDB Rx
- NOVARTIS ONCOLOGY has awarded the global professional advertising business for Gleevec to Cline Davis & Mann offshoot DDB Rx.
- Research articles 2006-01-01
- Syrrx Researchers Report Atomic Structure of c-KIT in Complex with Gleevec
- SAN DIEGO -- Syrrx Inc., a next-generation, structure-based drug discovery company, today reported the publication of an article further describing the atomic structure of c-Kit kinase in complex with Novartis' cancer drug GleevecR (also known as STI-571). Syrrx and Novartis are independently using the solved structure to design new anti-cancer...
- Research articles 2004-10-22
- Novartis' sales on track in third quarter; profits rise 7% as Diovan, Gleevec deliver.
- Swiss drug major Novartis has reported a solid financial performance for the third-quarter and nine-month periods ended September 30, 2003, helped by a strong showing from the cardiovascular treatment Diovan valsartan and the recently-launched anticancer drug Gleevec/Glivec imatinib mesylate. The Basel-headquartered firm posted a net profit of $1.27...
- Research articles 2003-10-27
- Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic use.
- M2 PRESSWIRE-18 February 2003-Research and Markets: Chronic Myeloid Leukemia - Gleevec resistance is opening a market for synergistic useC1994-2003 M2 COMMUNICATIONS LTD RDATE:02152003 With CML`s relatively low prevalence, the potential market for drugs launched for this indication historically has been insufficient...
- Research articles 2003-02-18
- Gleevec use
- The FDA has granted Gleevec approval as a second-line treatment for chronic myeloid leukemia. The product, manufactured by Novartis, has been used in the first-line treatment of the rare form of cancer since May 2001.
- Research articles 2004-01-19
- Novartis adds heart failure warning to Gleevec label
- Novartis Pharmaceuticals Corp. has revised the precautions section of the prescribing label for Gleevec imatinib mesylate to warn physicians about the potential for severe congestive heart failure and left ventricular dysfunction in patients taking the drug. In a recent article, severe congestive heart failure and left ventricular dysfunction were...
- Research articles 2007-01-01
- Vitamin C supplements may undercut the effectiveness of cancer drugs including Novartis AG's Gleevec , a US study showed
- Vitamin C supplements may undercut the effectiveness of cancer drugs including Novartis AG's Gleevec or Glivec, a US study showed. When used on human cancer cells treated with a form of vitamin C in lab dishes, chemotherapy drugs killed 30% to 70% fewer tumor cells than usual, the...
- Research articles 2008-10-06
- Novartis AG won approval for its Tasigna treatment for patients with a form of leukemia who are resistant or intolerant to Gleevec, another drug considered standard treatment for blood cancer
- Novartis AG won approval for its Tasigna treatment for patients with a form of leukemia who are resistant or intolerant to Gleevec, another drug considered standard treatment for blood cancer. In other action, the agency said that Cellcept, a Roche Holding AG drug used for certain organ-transplant patients,...
- Research articles 2007-11-05
- Novartis drug Tasigna® meets primary endpoint in pivotal trial against Gleevec® as first-line treatment in chronic myeloid leukemia patients
- - Tasigna produced faster and deeper responses compared to Gleevec as first-line treatment in Philadelphia chromosome-positive chronic myeloid leukemia - First registration study using molecular response as key indicator of patient outcomes; Bcr-Abl biomarker test measures very low levels of residual disease (1,2) - Tasigna is a potent...
- Research articles 2009-10-20
- Sun Pharma to market Gleevec's generic version [ ]
- MUMBAI: The $2.2 billion anti-cancer drug Gleevec, is about to face stiff competition from Indian shores. Mumbai-based Sun Pharma is among the first generic firms to have approached the US Food and Drug Administration to market a generic version in US market. Sun Pharma has filed a drug master file...
- Research articles 2006-08-26
- Research and Markets: Chronic Myelogenous Leukemia - New Targeted Therapies Take Aim at Gleevec
- DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/44c77e/chronic_myelogenou) has announced the addition of Decision Resources, Inc.'s new report "Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec" to ...
- Research articles 2009-11-18
- << Previous
- page 1 of 1
- Next >>
